MXPA05009526A - Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica. - Google Patents

Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.

Info

Publication number
MXPA05009526A
MXPA05009526A MXPA05009526A MXPA05009526A MXPA05009526A MX PA05009526 A MXPA05009526 A MX PA05009526A MX PA05009526 A MXPA05009526 A MX PA05009526A MX PA05009526 A MXPA05009526 A MX PA05009526A MX PA05009526 A MXPA05009526 A MX PA05009526A
Authority
MX
Mexico
Prior art keywords
cancer
viral infection
therapeutic treatment
myxoma virus
chronic viral
Prior art date
Application number
MXPA05009526A
Other languages
English (en)
Spanish (es)
Inventor
John C Bell
Original Assignee
Robarts Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robarts Res Inst filed Critical Robarts Res Inst
Publication of MXPA05009526A publication Critical patent/MXPA05009526A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/768Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24032Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MXPA05009526A 2003-03-07 2004-03-08 Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica. MXPA05009526A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45252103P 2003-03-07 2003-03-07
US45539303P 2003-03-18 2003-03-18
PCT/CA2004/000341 WO2004078206A1 (en) 2003-03-07 2004-03-08 Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection

Publications (1)

Publication Number Publication Date
MXPA05009526A true MXPA05009526A (es) 2005-12-15

Family

ID=32965588

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009526A MXPA05009526A (es) 2003-03-07 2004-03-08 Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.

Country Status (11)

Country Link
US (2) US7582614B2 (https=)
EP (1) EP1601376B1 (https=)
JP (2) JP4800924B2 (https=)
KR (1) KR101116858B1 (https=)
AU (1) AU2004216928B2 (https=)
CA (1) CA2517147C (https=)
IL (1) IL170601A (https=)
MX (1) MXPA05009526A (https=)
NZ (1) NZ541951A (https=)
RU (1) RU2362584C2 (https=)
WO (1) WO2004078206A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05009526A (es) * 2003-03-07 2005-12-15 Robarts Res Inst Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
AU2006222500B2 (en) * 2005-03-07 2011-09-01 Robarts Research Institute Use of a combination of Myxoma virus and rapamycin for therapeutic treatment
WO2007143538A2 (en) * 2006-06-01 2007-12-13 Robarts Research Institute Pike-a enhances infection by myxoma virus
MX2008015265A (es) 2006-06-01 2008-12-12 Robarts Res Inst Mutates del virus de mixoma para tratamiento del cancer.
CN104039333B (zh) 2011-06-09 2018-11-16 佛罗里达大学研究基金会有限公司 移植物抗宿主疾病的治疗或预防方法
WO2018091151A1 (en) * 2016-11-17 2018-05-24 Vcn Biosciences Sl Use of viral vectors in the treatment of retinoblastoma
WO2019048689A1 (en) 2017-09-11 2019-03-14 Imba - Institut Für Molekulare Biotechnologie Gmbh TUMOR ORGANOID MODEL
KR20190109379A (ko) * 2018-03-16 2019-09-25 바이로큐어 주식회사 암 치료를 위한 레오바이러스 및 믹소마폭스 바이러스의 병용
RU2699754C1 (ru) * 2018-05-08 2019-09-09 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Флуоресцирующая клеточная линия глиомы и способ её получения
WO2019227022A1 (en) 2018-05-25 2019-11-28 Bioventures, Llc Myxoma virus compositions and methods of use
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020036341A1 (ko) * 2018-08-17 2020-02-20 바이로큐어 주식회사 암 치료를 위한 다람쥐폭스 바이러스 및 믹소마폭스 바이러스의 병용
WO2020051248A1 (en) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
WO2020106880A1 (en) 2018-11-20 2020-05-28 Bioventures, Llc Cells for the production of viruses and methods of using the same
US11591616B1 (en) 2019-04-22 2023-02-28 Colorado State University Research Foundation Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
DE69722608T2 (de) 1996-01-25 2004-04-29 The University Court Of The University Of Glasgow, Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
JP2001510053A (ja) 1997-07-18 2001-07-31 カイロン コーポレイション レンチウイルスベクター
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
JP2003530301A (ja) 1999-04-15 2003-10-14 ウェルスタット バイオロジクス コーポレイション ウイルスを用いた新生物の処置
AU6175000A (en) * 1999-07-12 2001-01-30 Viron Therapeutics, Inc. Novel myxoma genes for immune modulation
MXPA05009526A (es) * 2003-03-07 2005-12-15 Robarts Res Inst Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
WO2007143545A2 (en) 2006-06-01 2007-12-13 Robarts Research Institute Tnf signaling in myxoma virus treatments

Also Published As

Publication number Publication date
KR101116858B1 (ko) 2012-03-06
JP2011157399A (ja) 2011-08-18
WO2004078206A1 (en) 2004-09-16
US20090317362A1 (en) 2009-12-24
HK1081099A1 (en) 2006-05-12
NZ541951A (en) 2008-03-28
JP4800924B2 (ja) 2011-10-26
RU2005131020A (ru) 2006-03-10
US20060263333A1 (en) 2006-11-23
CA2517147C (en) 2011-06-14
JP2006519789A (ja) 2006-08-31
CA2517147A1 (en) 2004-09-16
AU2004216928C1 (en) 2007-03-08
AU2004216928B2 (en) 2007-03-08
US8227440B2 (en) 2012-07-24
RU2362584C2 (ru) 2009-07-27
EP1601376B1 (en) 2012-05-30
EP1601376A1 (en) 2005-12-07
AU2004216928A1 (en) 2004-09-16
US7582614B2 (en) 2009-09-01
IL170601A (en) 2010-11-30
KR20050111349A (ko) 2005-11-24

Similar Documents

Publication Publication Date Title
MXPA05009526A (es) Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
WO2009091388A3 (en) Triazines and related compounds having antiviral activity, compositions and methods thereof
Ip et al. Therapeutic vaccination against chronic hepatitis C virus infection
WO2010118367A3 (en) Antiviral pyrimidines
EA200601575A1 (ru) Казеиновые пептиды и их терапевтическое применение
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
WO2008096831A1 (ja) 癌の治療剤
TW200510343A (en) Substituted dihydroquinazolines
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
WO2006050489A3 (en) Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
MXPA05008527A (es) Uso de artemisinina para tratar tumores inducidos por virus oncogenicos y para tratar infecciones virales.
WO2010093843A3 (en) Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
UA96412C2 (ru) Применение комбинации вируса миксомы и рапамицина для лечения
TW200633995A (en) Andrographolide derivatives to treat viral infections
SE0300034D0 (sv) Use of strains of the parapox ovis virus for producting antiviral pharmaceuticals and anticancer pharmaceuticals
EA201101036A1 (ru) Применение хлорида аммония в терапии
WO2004052905A3 (en) Antiviral nucleoside derivatives
WO2007029041A3 (en) Interferon lambda therapy for treatment of respiratory diseases
WO2002026249A3 (en) Methods for inhibition of viral infection
WO2004018002A3 (en) Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
MX2022001271A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
IN2011KN02819A (https=)
WO2003017943A3 (en) Therapeutic compositions and methods for treating viral infection

Legal Events

Date Code Title Description
FG Grant or registration